ASCENT Trial: Curative Novel Therapies in High-Risk Smoldering Myeloma

A New CELMoD Contender: SUCCESSOR-2 Highlights Mezigdomide’s Potential in Myeloma | EHA 2026

Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026

Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026

Treating Frail Myeloma Patients: AGMT MM04 Shows the Power of Isa-Rd | EHA 2026

Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026

Good News for Smoldering Myeloma: Decades of Data Show Better Survival | EHA 2026

BETA - What new imaging techniques are being testing for multiple myeloma?

BETA - What is the current role of a skeletal survey in diagnosing and monitoring multiple myeloma?

BETA - What are the different imaging modalities available and what is the advantage of each?

MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed Myeloma: | EHA 2026

A New Frontier in Myeloma: mRNA-2808 Targets BCMA, GPRC5D & FcRH5 with One Therapy | ASCO 2026

Blood-based Mass Spectrometry MRD Testing for Myeloma : EasyM | EHA 2026

BETA - How do t-cells develop and change? (2026 Update)

Myeloma Treatment Debates: Key CoMy 2026 Controversies and Clinical Decisions with Mohamad Mohty

DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed Myeloma | EHA 2026

Beyond One-Size-Fits-All: Martin Kaiser on Precision Diagnostics in Multiple Myeloma | EHA 2026